Hosted on MSN9h
Teva Stock Dives 14%. Why Its CEO Says It's A Victim.
Teva Pharmaceutical is a victim of its own success, Chief Executive Richard Francis said Wednesday as Teva stock plummeted on ...
Teva on track for worst intraday loss in years on guidance miss
Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below ...
dermatologyadvisor11h
FDA Warns Sanofi of Manufacturing Irregularities at Key Facility
The US FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients.
Time To Be Bullish On Sanofi Ahead Of Its Earnings
Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...